These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26748742)

  • 1. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
    Bowyer AE; Gosselin RC
    Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
    Marlar RA; Strandberg K; Shima M; Adcock DM
    Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
    Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
    Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level.
    Baig MA; Swamy KB
    Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
    Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
    Wilmot HV; Rakowski K; Gray E
    Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
    Kitchen S; Signer-Romero K; Key NS
    Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.